Interpretation of Sequential Measurements of Cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) Based on Analytical Imprecision and Biological Variation in the Monitoring of Ovarian Cancer
The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients...
Saved in:
| Published in | Clinical chemistry and laboratory medicine Vol. 39; no. 6; pp. 531 - 538 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article Conference Proceeding |
| Language | English |
| Published |
Berlin
Walter de Gruyter
01.06.2001
New York, NY |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1434-6621 |
| DOI | 10.1515/CCLM.2001.089 |
Cover
| Abstract | The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients with serological tumor markers should take into account the stochastic variation, i.e. the probability that observed increases and decreases may solely be due to analytical imprecision and normal intra-individual biological variation. The aim of this study was to provide a detailed characteristic of the within-subject mean steady state concentrations and the associated variability in healthy individuals with an age distribution representative for ovarian cancer patients. Thirty-one healthy women with a median age of 55 years comprised the study population. Sixteen blood samples were collected from each subject in four series, with four samples per series, over a period of approximately 1 year. We found that, i) natural logarithmic-transformed concentrations were more homogeneously distributed between individuals than the original concentrations, ii) the within-subject mean steady state levels, the standard deviations, and the coefficients of variation differed among subjects, and iii) the steady state variability differed among the markers. In conclusion, our data indicate that the assessment of sequential CA 125, CEA, and TPA concentrations is more complex than hitherto recognized. We suggest that it is necessary to adjust the assessment criteria to the type of marker, and that assessment may be facilitated if based on natural logarithmic transformed concentrations. |
|---|---|
| AbstractList | The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients with serological tumor markers should take into account the stochastic variation, i.e. the probability that observed increases and decreases may solely be due to analytical imprecision and normal intra-individual biological variation. The aim of this study was to provide a detailed characteristic of the within-subject mean steady state concentrations and the associated variability in healthy individuals with an age distribution representative for ovarian cancer patients. Thirty-one healthy women with a median age of 55 years comprised the study population. Sixteen blood samples were collected from each subject in four series, with four samples per series, over a period of approximately 1 year. We found that, i) natural logarithmic-transformed concentrations were more homogeneously distributed between individuals than the original concentrations, ii) the within-subject mean steady state levels, the standard deviations, and the coefficients of variation differed among subjects, and iii) the steady state variability differed among the markers. In conclusion, our data indicate that the assessment of sequential CA 125, CEA, and TPA concentrations is more complex than hitherto recognized. We suggest that it is necessary to adjust the assessment criteria to the type of marker, and that assessment may be facilitated if based on natural logarithmic transformed concentrations.The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients with serological tumor markers should take into account the stochastic variation, i.e. the probability that observed increases and decreases may solely be due to analytical imprecision and normal intra-individual biological variation. The aim of this study was to provide a detailed characteristic of the within-subject mean steady state concentrations and the associated variability in healthy individuals with an age distribution representative for ovarian cancer patients. Thirty-one healthy women with a median age of 55 years comprised the study population. Sixteen blood samples were collected from each subject in four series, with four samples per series, over a period of approximately 1 year. We found that, i) natural logarithmic-transformed concentrations were more homogeneously distributed between individuals than the original concentrations, ii) the within-subject mean steady state levels, the standard deviations, and the coefficients of variation differed among subjects, and iii) the steady state variability differed among the markers. In conclusion, our data indicate that the assessment of sequential CA 125, CEA, and TPA concentrations is more complex than hitherto recognized. We suggest that it is necessary to adjust the assessment criteria to the type of marker, and that assessment may be facilitated if based on natural logarithmic transformed concentrations. The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients with serological tumor markers should take into account the stochastic variation, i.e. the probability that observed increases and decreases may solely be due to analytical imprecision and normal intra-individual biological variation. The aim of this study was to provide a detailed characteristic of the within-subject mean steady state concentrations and the associated variability in healthy individuals with an age distribution representative for ovarian cancer patients. Thirty-one healthy women with a median age of 55 years comprised the study population. Sixteen blood samples were collected from each subject in four series, with four samples per series, over a period of approximately 1 year. We found that, i) natural logarithmic-transformed concentrations were more homogeneously distributed between individuals than the original concentrations, ii) the within-subject mean steady state levels, the standard deviations, and the coefficients of variation differed among subjects, and iii) the steady state variability differed among the markers. In conclusion, our data indicate that the assessment of sequential CA 125, CEA, and TPA concentrations is more complex than hitherto recognized. We suggest that it is necessary to adjust the assessment criteria to the type of marker, and that assessment may be facilitated if based on natural logarithmic transformed concentrations. |
| Author | Petersen, Per Hyltoft Dombernowsky, Per Tuxen, Malgorzata K. Sölétormos, György |
| Author_xml | – sequence: 1 givenname: Malgorzata K. surname: Tuxen fullname: Tuxen, Malgorzata K. – sequence: 2 givenname: György surname: Sölétormos fullname: Sölétormos, György – sequence: 3 givenname: Per Hyltoft surname: Petersen fullname: Petersen, Per Hyltoft – sequence: 4 givenname: Per surname: Dombernowsky fullname: Dombernowsky, Per |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14130280$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11506467$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kkuP0zAUhbMYxDxgyRZ5A5qRSLHjPJeZMAMVraaIwmI2lutcF0NiB9tF9C_zK3BomEpIrK6s89n3XN9zHp1ooyGKnhE8IxnJXjfNYjlLMCYzXFYn0RlJaRrneUJOo3PnvgYhy9LicXRKSIbzNC_Ool9z7cEOFjz3ymhkJPoI33egveIdWgJ3Owt9OLpRargWYFEd1C1oRJIMXTb1WK9eBdEKpQ30G7s3WokH7LK5qa8Q1y1aK-d2gFam2w8weNXCEVqvAnTNHbQo-Kg17_ZeiWBi3gd7QrnR3vjItTKd2f6RPnOrDr6VRv4LoGVo7I1Vejvavfsx6nqy_SR6JHnn4OlUL6JPtzfr5l28uHs7b-pFLGhW-BhyWeZpUUBJW1lKISinbSmTMuVVIaRsZQJphQssk4S0CaloQdoWqg0Ap6SU9CJ6eXh3sCb8pPOsV05A13ENZudYQXBVJSQP4PMJ3G16aNlgVc_tnv3dTgBeTAB3YVxpwxzKHbmUUJyUOHDxgRPWOGdBHhHMxmSwMRlsTAYLyQg8_YcX6rB_b7nq_ntr6qKch58PLbj9xoLXImMf1ilrVrf3b3D-nt3T36klzpI |
| CitedBy_id | crossref_primary_10_1016_j_cca_2011_11_012 crossref_primary_10_1159_000438861 crossref_primary_10_1177_0004563214534636 crossref_primary_10_4155_fsoa_2017_0023 crossref_primary_10_1177_0004563214555163 crossref_primary_10_1515_cclm_2021_0283 crossref_primary_10_1515_CCLM_2004_073 crossref_primary_10_1515_cclm_2021_0725 crossref_primary_10_1080_00365510310000439 crossref_primary_10_1373_clinchem_2004_040659 crossref_primary_10_1007_s12094_012_0756_8 |
| Cites_doi | 10.1200/JCO.1996.14.5.1545 10.1016/0305-7372(95)90002-0 10.1093/clinchem/29.1.25 10.1093/clinchem/36.9.1625 10.1093/clinchem/40.9.1671 10.1159/000217761 10.1200/JCO.2000.18.8.1733 10.1006/gyno.1999.5414 10.1016/0021-9681(70)90055-X 10.1093/clinchem/36.2.265 10.1002/ijc.2910510112 10.1515/CCLM.2000.066 10.1177/000456329102800301 10.1093/annonc/6.suppl_2.S31 10.1016/0090-8258(92)90031-D 10.3109/10408368909106595 10.1016/S0065-2423(08)60208-5 10.1097/00000658-198509000-00006 10.1515/CCLM.1999.089 10.1093/clinchem/27.3.493 10.1016/0002-9378(84)90035-8 10.1136/bmj.298.6689.1659 10.1016/0009-9120(95)91342-Z 10.1093/clinchem/39.10.2077 10.1177/000456329102800313 |
| ContentType | Journal Article Conference Proceeding |
| Copyright | 2002 INIST-CNRS |
| Copyright_xml | – notice: 2002 INIST-CNRS |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1515/CCLM.2001.089 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry |
| EndPage | 538 |
| ExternalDocumentID | 11506467 14130280 10_1515_CCLM_2001_089 ark_67375_QT4_CPFZD06K_Z |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Balkan Clinical Laboratory Federation |
| GroupedDBID | --- -~0 .GJ 0R~ 0~D 29B 36B 4.4 53G 5GY 5RE 9-L AAAEU AABBZ AAFPC AAGVJ AAILP AALGR AAONY AAOQK AAOWA AAPJK AAQCX AAWFC AAXCG ABAOT ABAQN ABFKT ABFQV ABIQR ABJNI ABLJU ABMIY ABPLS ABRDF ABRQL ABUVI ABVMU ABWLS ABXMZ ABYBW ACEFL ACGFS ACIWK ACMKP ACPMA ACPRK ACXLN ACZBO ADALX ADDWE ADEQT ADGQD ADGYE ADOZN ADUQZ AEDGQ AEGVQ AEICA AEJTT AEKEB AENEX AEQDQ AERZL AEXIE AFAUI AFBAA AFBQV AFCXV AFGDO AFGNR AFQUK AFRAH AFYRI AGBEV AGGNV AHOVO AHVWV AHXUK AI. AIERV AIKXB AJATJ AJHHK AKXKS ALMA_UNASSIGNED_HOLDINGS ALUKF ALYBR AMAVY ASPBG ASYPN AVWKF AZFZN AZMOX BAKPI BBCWN BCIFA BSCLL BWHEM CAG CGQUA COF CS3 DA2 DBYYV DU5 EJD F5P FSTRU HZ~ IL9 IY9 KDIRW N9A O9- OVD P2P PQQKQ QD8 RDG SA. SLJYH TEORI UK5 VH1 WTRAM ~Z8 AARRE AAYXX ABDRH ACDEB ACRPL ACUND ACYCL ADNMO ADNPR AECWL AFBDD AFSHE AGQPQ AIWOI CITATION DSRVY LVMAB .55 1CY 354 AAFNC AAOTM AASQH ABUBZ EBS EMOBN IQODW OBC OBS OEB OES OHH X7M CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c357t-e6f86477e83df8fcc3a3d8f284a97cffdf2e49070f221d219371dde9beea318f3 |
| ISSN | 1434-6621 |
| IngestDate | Sat Sep 27 22:11:45 EDT 2025 Wed Feb 19 01:24:59 EST 2025 Wed Apr 02 07:47:36 EDT 2025 Wed Oct 01 03:08:39 EDT 2025 Thu Apr 24 23:11:43 EDT 2025 Wed Oct 30 09:36:56 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Human Concentration factor Variability Tissue polypeptide specific antigen Tumoral marker Malignant tumor Female genital diseases Ovarian diseases Carcinoembryonic antigen Ovary Surveillance CA 125 antigen Female |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MeetingName | 8th Meeting of the Balkan Clinical Laboratory Federation, Sinaia, 20-23 September 2000 |
| MergedId | FETCHMERGED-LOGICAL-c357t-e6f86477e83df8fcc3a3d8f284a97cffdf2e49070f221d219371dde9beea318f3 |
| Notes | istex:BD810E5740E3A42E59F3923D75F171EA3D235FB8 cclm.2001.089.pdf ark:/67375/QT4-CPFZD06K-Z ArticleID:cclm.39.6.531 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 11506467 |
| PQID | 71099216 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_71099216 pubmed_primary_11506467 pascalfrancis_primary_14130280 crossref_primary_10_1515_CCLM_2001_089 crossref_citationtrail_10_1515_CCLM_2001_089 istex_primary_ark_67375_QT4_CPFZD06K_Z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2001-06-01 |
| PublicationDateYYYYMMDD | 2001-06-01 |
| PublicationDate_xml | – month: 06 year: 2001 text: 2001-06-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Berlin New York, NY |
| PublicationPlace_xml | – name: Berlin – name: New York, NY – name: Germany |
| PublicationTitle | Clinical chemistry and laboratory medicine |
| PublicationTitleAlternate | Clinical Chemistry and Laboratory Medicine |
| PublicationYear | 2001 |
| Publisher | Walter de Gruyter |
| Publisher_xml | – name: Walter de Gruyter |
| References | Fraser CG (p_13) 1990; 36 p_23 Gion M (p_31) 1995; 6 p_25 Bast RC, Jr. (p_7) 1984; 149 Krebs HB (p_12) 1986; 67 Fraser CG (p_28) 1991; 28 Lytken Larsen M (p_24) 1991; 28 Martin EW (p_29) 1985; 202 p_16 Sölétormos G (p_33) 1993; 39 Rustin GJ (p_1) 1996; 14 Harris KH (p_20) 1983; 29 p_4 p_34 p_3 Rustin GJ (p_2) 2000; 18 p_6 p_14 p_8 Gadducci A (p_9) 1990; 11 Westgard JO (p_17) 1981; 27 Harris EK (p_21) 1990; 36 Chan DW (p_5) 1999 Plebani M (p_32) 1996; 16 p_30 p_10 Fraser CG (p_15) 1994; 40 p_11 Gowans EMS (p_19) 1989; 13 Andersen M (p_22) 1996; 3 |
| References_xml | – volume: 14 start-page: 1545 year: 1996 ident: p_1 publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.5.1545 – ident: p_3 doi: 10.1016/0305-7372(95)90002-0 – volume: 29 start-page: 25 year: 1983 ident: p_20 publication-title: Clin Chem doi: 10.1093/clinchem/29.1.25 – volume: 36 start-page: 1625 year: 1990 ident: p_13 publication-title: Clin Chem doi: 10.1093/clinchem/36.9.1625 – volume: 67 start-page: 473 year: 1986 ident: p_12 publication-title: Obstet Gynecol – volume: 40 start-page: 1671 year: 1994 ident: p_15 publication-title: Clin Chem doi: 10.1093/clinchem/40.9.1671 – volume: 16 start-page: 2249 year: 1996 ident: p_32 publication-title: Anticancer Res – ident: p_11 doi: 10.1159/000217761 – volume: 13 start-page: 327 year: 1989 ident: p_19 publication-title: Biochim Clin – volume: 18 start-page: 1733 year: 2000 ident: p_2 publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.8.1733 – ident: p_4 doi: 10.1006/gyno.1999.5414 – ident: p_16 doi: 10.1016/0021-9681(70)90055-X – volume: 36 start-page: 265 year: 1990 ident: p_21 publication-title: Clin Chem doi: 10.1093/clinchem/36.2.265 – ident: p_10 doi: 10.1002/ijc.2910510112 – ident: p_34 doi: 10.1515/CCLM.2000.066 – volume: 28 start-page: 207 year: 1991 ident: p_28 publication-title: Ann Clin Biochem doi: 10.1177/000456329102800301 – volume: 6 start-page: S31 year: 1995 ident: p_31 publication-title: Ann Oncol doi: 10.1093/annonc/6.suppl_2.S31 – ident: p_8 doi: 10.1016/0090-8258(92)90031-D – ident: p_25 doi: 10.3109/10408368909106595 – ident: p_6 doi: 10.1016/S0065-2423(08)60208-5 – volume: 202 start-page: 310 year: 1985 ident: p_29 publication-title: Ann Surg doi: 10.1097/00000658-198509000-00006 – ident: p_23 doi: 10.1515/CCLM.1999.089 – volume: 27 start-page: 493 year: 1981 ident: p_17 publication-title: Clin Chem doi: 10.1093/clinchem/27.3.493 – volume: 149 start-page: 553 year: 1984 ident: p_7 publication-title: Am J Obstet Gynecol doi: 10.1016/0002-9378(84)90035-8 – ident: p_14 doi: 10.1136/bmj.298.6689.1659 – volume: 3 start-page: 197 year: 1996 ident: p_22 publication-title: Endocrinol Metab – ident: p_30 doi: 10.1016/0009-9120(95)91342-Z – volume: 39 start-page: 2077 year: 1993 ident: p_33 publication-title: Clin Chem doi: 10.1093/clinchem/39.10.2077 – volume: 11 start-page: 127 year: 1990 ident: p_9 publication-title: Eur J Gynaecol Oncol – volume: 28 start-page: 272 year: 1991 ident: p_24 publication-title: Ann Clin Biochem doi: 10.1177/000456329102800313 – start-page: 722 year: 1999 ident: p_5 publication-title: Philadelphia: WB Saunders |
| SSID | ssj0015547 |
| Score | 1.6779417 |
| Snippet | The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients... |
| SourceID | proquest pubmed pascalfrancis crossref istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 531 |
| SubjectTerms | Adult Aged Analysis of Variance Biological and medical sciences Biometry CA-125 Antigen - blood Carcinoembryonic Antigen - blood Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Immunoassay - standards Immunoassay - statistics & numerical data Longitudinal Studies Medical sciences Middle Aged Ovarian Neoplasms - diagnosis Ovarian Neoplasms - immunology Quality Control Reference Values Tissue Polypeptide Antigen - blood Tumors |
| Title | Interpretation of Sequential Measurements of Cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) Based on Analytical Imprecision and Biological Variation in the Monitoring of Ovarian Cancer |
| URI | https://api.istex.fr/ark:/67375/QT4-CPFZD06K-Z/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/11506467 https://www.proquest.com/docview/71099216 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAZK databaseName: De Gruyter Complete Journal Package issn: 1434-6621 databaseCode: AGBEV dateStart: 19950101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.degruyterbrill.com omitProxy: false ssIdentifier: ssj0015547 providerName: Walter de Gruyter |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dU9NAEL_hY0Z9U0StH3gP6sCUKPlomjyWEGCE0goBgZfMJbk4jJAyIXUs_7L_hLt3l49iGUdfSsltL2n3t7d7d7-9JeSdbTCLGzHTjChyNIs5uuZy7mpd29IxtRhiFNzR7R_Yu8fW59PO6dz8sMFaGhfRx_h2Zl7J_2gVroFeMUv2HzRbdQoX4D3oF15Bw_D6p45nuhqvTGyMy8JtYjdAqRb3z6c3z4tZTEOIFyWjurgQuSTVqqGgecSIC2RaFnhwZxtCFbHz28N37w0XdRRjQaJsxK-ifCIq6pTCKOj3lJTgago9Y2kImP_CaJXwpmwwRNk2etakLWjS7HIiF9svrq5zVQ5IdCQPjxJNP2C6z5qczSsxTuWKzz0S7Zn6HtVKxfGpfyCTlS6_jfJbVrDGii_SB1x73w8Gh_2BIDfuTPDapp3XexC7Z_vBYDtoD32YEhzJ3ob1HbYG_U3_8GDw9WjvrNlULrE0qGByIBfEhTb8Ijv5eFKypqW_sExLs22Z5F06FHk6kzKcpnfoKIfH1X_OTB_WEcd9eN5-H5cv8IRZt3bWJUHhjg-vmJU6BiWGszFPFg0TRvMFstjb2fRPqp01CB9FwaHywdW5s3DTT1O3nIrTFnHI-Ym8YXYDik1lzZf7J2UiOAsek-U6bZUOKyt5QuZ4tkQeeqVlLJEHfWUMT8mvaRugo5TWNkCbNoBNEjtUQZUC8umq18O_a-v0LvorsVXAPrQDXKnEPW3gvpYC1K9RgXkKD1JjnjYwLzqpMU8rzNOLjALmaY15fF6FefXcy-R42w-8XU0VPtFis9MtNG6nDiaIc8dMUieNY5OZiZNCJMncbpymSWpwywVnnRqGnkDMYXZ1CFPciHMGPjo1n5GFbJTxF4RGXYvpG5YecaZbRmwzmL6A042jJIGh2HBaZL1UcxirqgBYnOYyxNUBQEWIqMBitXoIqGiRD5X4tTwO515BgZlKiuXfkUPa7YRfAiv0htvnWxv2XnjeIitToKq7VUhukbclykKAC-5nsoyPxjch0shdQ7db5LkEX_1ZPDcVQsCXf-v8FXlUG_xrslDkY_4GZhlFtKIM5zdGSCtP |
| linkProvider | Walter de Gruyter |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=Clinical+chemistry+and+laboratory+medicine&rft.atitle=Interpretation+of+sequential+measurements+of+cancer+antigen+125+%28CA+125%29%2C+carcinoembryonic+antigen+%28CEA%29%2C+and+tissue+polypeptide+antigen+%28TPA%29+based+on+analytical+imprecision+and+biological+variation+in+the+monitoring+of+ovarian+cancer&rft.au=TUXEN%2C+Malgorzata+K&rft.au=S%C3%96LETORMOS%2C+Gy%C3%B6rgy&rft.au=HYLTOFT+PETERSEN%2C+Per&rft.au=DOMBERNOWSKY%2C+Per&rft.date=2001-06-01&rft.pub=Walter+de+Gruyter&rft.issn=1434-6621&rft.volume=39&rft.issue=6&rft.spage=531&rft.epage=538&rft_id=info:doi/10.1515%2FCCLM.2001.089&rft.externalDBID=n%2Fa&rft.externalDocID=14130280 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon |